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Abstract 10 
Tauopathies are a group of neurodegenerative diseases characterised by the progressive accumulation 11 
across the brain of hyperphosphorylated aggregates of the microtubule-associated protein tau that 12 
vary in isoform composition, structural conformation and localisation. Tau aggregates are most 13 
commonly deposited within neurons but can show differential association with astrocytes, depending 14 
on the disease. Astrocytes, the most abundant neural cells in the brain, play a major role in synapse 15 
and neuronal function, and are a key component of the glymphatic system and blood brain barrier. 16 
However, their contribution to tauopathy progression is not fully understood. Here we present a brief 17 
overview of the association of tau with astrocytes in tauopathies. We discuss findings that support a 18 
role for astrocytes in the uptake and spread of pathological tau, and we describe how alterations to 19 
astrocyte phenotype in tauopathies may cause functional alterations that impedes their ability to 20 
support neurons and/or cause neurotoxicity. The research reviewed here further highlights the 21 
importance of considering non-neuronal cells in neurodegeneration and suggests that astrocyte-22 
directed targets that may have utility for therapeutic intervention in tauopathies. 23 
Contribution to the field: Several neurodegenerative diseases, including Alzheimer’s disease are 24 
characterised by the presence of abnormal tau deposits in affected brain regions, that is closely 25 
associated with synapse loss and neurodegeneration. Astrocytes, the most abundant neural cell type 26 
are an intrinsic component of synapses and regulate neuronal circuits. Recent evidence has 27 
highlighted an important contribution of astrocytes to the prion-like propagation of abnormal tau in 28 
Alzheimer’s disease and related tauopathies. We discuss the evidence linking astrocytes with 29 
tauopathies, including their newly described roles in tau uptake/spread, highlighting the importance 30 
of continued work in this area.  31 
1 Introduction 32 
Tauopathies are a heterogeneous group of neurodegenerative diseases in which the deposition of 33 
hyperphosphorylated tau aggregates in affected brain regions accompanies synapse and neuron loss 34 
(Guo et al., 2016). Primary tauopathies exhibit tau aggregates as the predominant pathological 35 
hallmark and include a diverse family of frontal-temporal lobar dementia (FTLD) subtypes referred 36 
to as FTLD-tau, and includes progressive supranuclear palsy (PSP) and Pick’s disease (PiD). 37 
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Alzheimer’s disease (AD) is considered a secondary tauopathy owing to the presence of extracellular 38 
amyloid-beta (Aß) plaques, and is the most common cause of dementia (Prince et al., 2014).  39 
Tau proteins undergo several post-translational and other modifications in disease (Guo et al., 2016). 40 
Modified forms of tau spreads from the original site of deposition to anatomically connected regions 41 
by a “prion-like” mechanism, whereby tau proteopathic seeds passively recruit tau monomers (Jucker 42 
and Walker, 2018). The mechanisms underlying tau release, uptake and spread are not fully 43 
understood. It has long been acknowledged that in some tauopathies astrocytes accumulate tau 44 
leading to characteristic disease neuropathology. Accumulating evidence now suggests that 45 
astrocytes may actively participate in tau spread and/or clearance mechanisms by actively 46 
internalising tau. This review summarises the association of tau with astrocytes in tauopathies, and 47 
discusses the evidence implicating astrocytes in tau spread, as well as the impact of tauopathy brain 48 
environments on physiological astrocytic functions.  49 
2 Tau protein 50 
Human tau is encoded by the MAPT gene on chromosome 17 which comprises 16 exons. Exons 2, 3 51 
and 10 undergo alternative splicing to produce the six main tau isoforms present in the adult human 52 
central nervous system (CNS) (Andreadis, 2005). Alternative splicing of exon 10 gives rise to tau 53 
isoforms containing either three or four microtubule binding repeats (referred to as 3R or 4R tau) in 54 
the C-terminal region, and alternative splicing of exons 2 and 3 produces tau proteins with zero, one 55 
or two inserts in the N-terminal tail (0N, 1N or 2N tau, respectively). A conserved proline-rich 56 
domain is found between these two spliced regions and is known to be important for tau interactions 57 
with other proteins, including actin (He et al., 2009). Tau isoforms are developmentally regulated; the 58 
shortest 0N3R isoform is expressed in the fetal brain whereas in the adult human brain 3R and 4R 59 
isoforms are equally represented (Goedert and Jakes, 1990). Tau has a number of key functions, the 60 
most recognised of which is stabilising microtubules in the axons of neurons, however tau roles in 61 
other important physiological functions such as axonal transport, DNA protection, cell signalling at 62 
the membrane, and synaptic vesicle release, have been described (Wang and Mandelkow, 2016; Guo 63 
et al., 2017). Tau is primarily expressed in neurons (Binder, 1985), but is known to be expressed to a 64 
lesser extent in glial cells (Zhang et al., 2014; Darmanis et al., 2015; Seiberlich et al., 2015; 65 
McKenzie et al., 2018).  66 
Monomeric tau is water soluble and resists aggregation (Wang and Mandelkow, 2016). In 67 
tauopathies, tau undergoes extensive post-translational and other modifications including, but not 68 
limited to, phosphorylation, acetylation, nitration, SUMOylation, glycosylation, ubiquitination, 69 
cleavage and aggregation (Guo et al., 2017). The best studied of these is phosphorylation. There are 70 
85 potential phosphorylation sites in 2N4R tau (Hanger et al., 2009) and increased phosphorylation 71 
of tau, alongside other tau modifications, can reduce tau affinity for microtubules, increase 72 
cytoplasmic tau concentrations and  promote tau oligomerisation and aggregation (Guo et al., 2017). 73 
Differential extents of tau modifications lead to the accumulation of heterogeneous pools of modified 74 
tau between, and within, different tauopathies. Recently, Dujardin et al. (2020) found variations in 75 
relative abundance of soluble, oligomeric and seed-competent species of hyperphosphorylated tau in 76 
tauopathy brain. Specific post-translational modifications were found to influence tau seeding 77 
capacity, and tau seeding potential strongly correlated with the rate of clinical symptoms/disease 78 
progression. 79 
The isoform composition of tau aggregates, as well as the structure of tau filaments, also differs 80 
between tauopathies. In AD, both paired helical and straight filaments contain identical protofilament 81 
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cores comprising residues 306-378 that define the aggregatory seed/core (Fitzpatrick et al., 2017). 82 
This structure differs from the folds of tau filaments observed in Pick’s disease (Falcon et al., 2018) 83 
and tau filaments of chronic traumatic encephalopathy (CTE) have a unique hydrophobic core 84 
(Falcon et al., 2019). A novel fold in corticobasal degeneration (CBD) tau has now also been 85 
discovered (Zhang et al., 2020). These features may be important for the tau lesions that arise in 86 
different tauopathies (Table 1). 87 
3 Astrocytes in health and disease 88 
Astrocytes are organised into distinct domains, and each astrocyte can connect with thousands of 89 
neurons, allowing them to coordinate synaptic activity in the CNS (Parpura et al., 1994; Oberheim et 90 
al., 2006). Astrocytes were long considered as supporting cells in the brain, providing metabolic and 91 
nutritional support for neurons. However, astrocytes are critical for neuronal function due to their 92 
ability to sense changes in neuronal activity through their complement of cell surface receptors, and 93 
to modulate neuronal activity by releasing gliotransmitters and gliomodulators, as well as controlling 94 
the availability of glutamate, GABA and energy substrates (Parpura et al., 1994; Volterra and 95 
Meldolesi, 2005; Choi et al., 2014). Hence, astrocytes are now known to be actively involved in 96 
synaptic transmission (Santello et al., 2019), neural circuit maintenance (Mederos et al., 2018) and 97 
long-term potentiation (Lushnikova et al., 2009). In addition, astrocytic end-feet are a structural 98 
component of the blood-brain barrier (BBB), and together with endothelial cells and pericytes have a 99 
central role in the regulation of blood flow (Sofroniew and Vinters, 2010). Furthermore, astrocyte 100 
end-feet are crucial for the glymphatic system of the brain, a perivascular network that allows for 101 
exchange of interstitial and cerebrospinal fluid (CSF), providing a route for clearance of molecules 102 
and proteins including Aβ (Iliff et al., 2012; Simon et al., 2018).  103 
In the neurodegenerative brain, astrocytes undergo pathological changes in responses to changes in 104 
the local brain environment that precede neuronal loss (Kersaitis et al., 2004). These morphologically 105 
and functionally modified astrocytes are often termed ‘reactive’. Reactive astrocytes show 106 
considerable heterogeneity related to their localisation in the brain and the severity and length of 107 
injury/insult to their local environment (Zamanian et al., 2012).  Reactive astrocytes are traditionally 108 
characterised by increased levels of glial fibrillary acidic protein (GFAP), which allows cytoskeletal 109 
and morphological arrangements as astrocytes alter their function (Kamphuis et al., 2015; Acosta et 110 
al., 2017). The accumulation of GFAP-immunopositive astrocytes is common in neurodegenerative 111 
diseases. For example, reactive astrocytes are often found surrounding plaques in AD (Bouvier et al., 112 
2016; Osborn et al., 2016). Indeed, levels of GFAP-reactive astrocytes are closely associated with 113 
dementia in AD (Perez-Nievas et al., 2013). While increased GFAP is also found in aged brain 114 
(Wruck and Adjaye, 2020), new evidence suggests that there are subgroups of astrocytes, with 115 
varying levels of GFAP expression, that distinguish aging from AD, at least in mice (Habib et al., 116 
2020). Alterations in GFAP expression have also been noted in primary tauopathies including PSP, 117 
PiD and corticobasal degeneration (CBD) (Ferrer et al., 2014).  118 
Functional changes in reactive astrocytes are well-documented and include impaired gliotransmitter 119 
release (Piacentini et al., 2017), alterations in calcium signalling (Shigetomi et al., 2019), deficient 120 
ability to regulate glutamate levels at neuronal synapses and aberrant GABA release (Acosta et al., 121 
2017). In addition, astrocytes are now recognised to contribute to neuroinflammatory responses that 122 
accelerate the progression of neurodegenerative diseases (Phillips et al., 2014; Bouvier et al., 2016; 123 
Bright et al., 2019). For example, reactive astrocytes increase their production and release of pro-124 
inflammatory cytokines, complement components, and reactive oxygen species, alongside 125 
downregulating anti-inflammatory and repair proteins to induce neurotoxicity in diseased 126 
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environments (Lian et al., 2015; Bouvier et al., 2016; Leyns and Holtzman, 2017; Sadick and 127 
Liddelow, 2019). Recent seminal findings proposed that astrocytes respond to their local 128 
environment by adopting “A1-neurotoxic” or “A2-neuroprotective”  phenotypes (Liddelow et al., 129 
2017). Secretion of Il-1α, TNFα, and C1q by microglia in response to damage, induces astrocytes to 130 
upregulate their expression of a specific cluster of “A1” genes, lose their trophic and synaptic support 131 
for neurons, and induce neuron death (Liddelow et al., 2017). Markers of A1 astrocytes are 132 
upregulated in AD and other neurodegenerative diseases (Liddelow et al., 2017), strongly implicating 133 
microglia-astrocyte communications in neurodegeneration. However, it is likely that there is a 134 
spectrum of reactive astrocyte states in different brain regions, throughout aging and disease 135 
progression (Boisvert et al., 2018; Habib et al., 2020), similar to dynamic microglial responses in 136 
disease (Vainchtein and Molofsky, 2020).  137 
4 The association of astrocytes with tauopathy 138 
Tau aggregates accumulate in both neurons and astrocytes in different tauopathies. In AD, tau 139 
aggregates containing both 3R and 4R tau deposit as intraneuronal neurofibrillary tangles and there is 140 
scant evidence of astrocytic tau inclusions (Garwood et al., 2017). In contrast, astrocytic tau 141 
pathology is the defining feature of several FTLD-tau subtypes (Table 1). In PSP, a 142 
neuropathological diagnosis criterion is ‘tufted’ astrocytes that show 4R tau aggregates in their 143 
proximal processes (Cairns et al., 2007; Kovacs and Budka, 2010). CBD has extensive clinical 144 
overlap with PSP. In CBD, astrocytic plaques containing 4R tau deposits that mark distal and end 145 
processes are an exclusive feature in most (Forrest et al., 2019), but not all (Ling et al., 2020) cases. 146 
Thread-like tau-positive astrocytic processes are also common in CBD (Dickson et al., 2011; Ling et 147 
al., 2016). Argyrophilic grain disease (AGD) is a rare tauopathy that is characterised by 4R tau-148 
immunopositive astrocytes, described as thorn-shaped and fuzzy/bush-like, in the medial temporal 149 
lobe (Botez et al., 1999; Saito et al., 2004; Forrest et al., 2019). In contrast, PiD is typically 150 
characterised by neuronal 3R tau inclusions, predominantly in granular neurons in the hippocampus, 151 
frontal and temporal cortices (Dickson, 2001; Josephs et al., 2011). ‘Ramified’ astrocytes 152 
immunopositive for tau have also been reported in PiD, but they are not considered a major 153 
pathological hallmark of the disease (Dickson et al., 2011; Ferrer et al., 2014). Several rarer 154 
tauopathy subtypes that show 4R tau-immunopositive globular inclusions, predominantly in 155 
oligodendrocytes, and more rarely in the cytoplasm and proximal processes of astrocytes, are 156 
collectively termed globular glial tauopathy (GGT) (Ahmed et al., 2013).  157 
A spectrum of FTLD-tau subtypes that accumulate both 3R and 3R tau in neurofibrillary tangles 158 
(NFTs) typically occurring in cognitively normal aged individuals is referred as primary age-related 159 
tauopathy (PART) (Crary et al., 2014; Jellinger et al., 2015). Depending on the co-occurrence of Aß 160 
pathology, PART can be histologically classified as “definite PART” in the absence of Aß deposits, 161 
or “possible PART” when a limited number of Aß deposits are present (Crary et al., 2014). Although 162 
the neuropathological characteristics of PART can overlap with other tauopathies, particularly AD, 163 
PART shows a lower threshold of amyloid load, and appears to have a more limited impact on 164 
cognition (Crary et al., 2014). Tau pathology in PART is predominantly neuronal and found in the 165 
CA2 hippocampal subfield, with little evidence of astrocytic tau deposits (Crary et al., 2014; 166 
Jellinger, 2018). In contrast, age-related tau astrogliopathy (ARTAG) describes a spectrum of 167 
abnormal tau pathology, predominantly in the aged brain, that is characterised by thorn-shaped and 168 
granular or fuzzy astrocytes containing phosphorylated tau (Kovacs et al., 2016; Kovacs, 2018). 169 
ARTAG can present alongside more typical tau pathology in tauopathies such as CBD  (Kovacs et 170 
al., 2018, 2020), but is not always linked with dementia (Lace et al., 2012). In a recent detailed 171 
review, Kovacs et al. (2020) describe two distinct distribution patterns of ARTAG. They describe 172 
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ARTAG as a consequence of repeated mechanical damage (related to CTE), or chronic damage such 173 
as blood-brain barrier dysfunction. Furthermore, they propose that the location and type (white 174 
versus grey matter) of ARTAG pathology may result in decompensation of cognitive functions, the 175 
rate of which may be influenced by co-existing pathologies (Kovacs, 2020). It is important to note 176 
that the presence of astrocytic tau accumulations in the absence of dementia may suggest that tau-177 
containing astrocytes are not damaging in tau-associated neurodegeneration, or at least in ARTAG, 178 
and may internalise tau aggregates as a means of clearing damaging protein species.  179 
Finally, chronic traumatic encephalopathy (CTE) is caused by mild repetitive head injuries. 3R and 180 
4R tau-positive aggregates are common in CTE, however the tau aggregates that accumulate in 181 
astrocytes are predominantly 4R and localize in astrocytes near small vessels in the cerebral sulci of 182 
the frontal and temporal cortices (McKee et al., 2013, 2015; Stein et al., 2014). Thorn-shaped 183 
astrocytes are also observed subpial and periventricular regions, an interesting link to ARTAG 184 
(McKee et al., 2016; Kovacs et al., 2020).  185 
5 Do astrocytes contribute to tau pathology spread? 186 
Neurofibrillary tangles have long been acknowledged to follow a stereotypical temporospatial pattern 187 
of spread from the entorhinal cortex as AD progresses (Braak et al., 2011). Recent evidence indicates 188 
that differences in the tau species that deposit in characteristic tau lesions may confer specific 189 
neuronal vulnerabilities and/or prion-like spread of tau (Clavaguera et al., 2013; Dujardin et al., 190 
2020). Mouse models that express wild-type 3R and 4R human tau isoforms in appropriate ratios 191 
recapitulate the same cell type vulnerabilities that typify human tauopathies when injected with 192 
human tau extracts, including the development of tufted astrocytes in PSP tau-injected mice, and 193 
astroglial plaques in CBD tau-injected mice (He et al., 2020). These data raise the possibility that 194 
astrocytes actively contribute to the spread of pathological forms of tau, particularly in PSP and 195 
CBD. That tau spreads in a prion-like manner trans-synaptically along anatomical connections was 196 
elegantly shown in transgenic mice in which mutant human (P301L) FTLD-causing tau expression 197 
was restricted to layer II neurons in the entorhinal cortex. Following local tau aggregation, tau 198 
“seeds” were found to spread to the hippocampus and onwards as mice aged (De Calignon et al., 199 
2012; Liu et al., 2012). Notably, PHF1-positive tau was detected in GFAP-positive astrocytes in the 200 
hippocampus of older mice, suggesting that astrocytes internalise and may contribute to tau spread 201 
(De Calignon et al., 2012) (Figure 1). 202 
Heparan sulfate proteoglycans (HSPGs) are a well-conserved group of proteoglycans expressed on 203 
the cell surface of astrocytes and neurons (Turnbull et al., 2001; Sarrazin et al., 2011) that mediate 204 
targeted endocytosis (Turnbull et al., 2001), including that of purified prion proteins in vitro 205 
(Schonberger et al., 2003; Horonchik et al., 2005). HSPGs were recently shown to interact with 206 
protein aggregates including α-synuclein, Aβ and tau (Kanekiyo et al., 2011; Holmes et al., 2013; 207 
Ihse et al., 2017). HSPGs regulate the uptake of synthetic tau fibrils (Holmes et al., 2013) and human 208 
brain-derived tau (Puangmalai et al., 2020) in human immortalised cell lines and mouse primary 209 
neuronal cultures. HSPGs vary in the length of their glycosaminoglycan chains and sulfation 210 
patterns, properties that are important for tau uptake in human embryonic kidney cells (Stopschinski 211 
et al., 2018) and human iPSC derived neurons (Rauch et al., 2018). Interestingly, tau fibrils are 212 
efficiently internalised in a HSPG-dependent manner by primary astrocytes exogenously expressing 213 
transcription factor EB (TFEB), a master regulator of lysosomal biogenesis (Martini-Stoica et al., 214 
2018). In contrast, monomeric tau appears to be taken up by astrocytes using an HSPG-independent 215 
mechanism (Perea et al., 2019). Together this suggests that multiple mechanisms are involved in tau 216 
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uptake by astrocytes, that may be specific to tau aggregation state or conformation, as well as the 217 
HSPG profile of the cell type (Tselnicker et al., 2014).  218 
HSPGs can also partner with cell surface receptors to mediate the intake of protein aggregates. For 219 
example, HSPGs interact with members of the low-density lipoprotein receptor (LDLR) such as 220 
LRP1, to facilitate Aβ uptake and degradation by astrocytes (Kanekiyo and Bu, 2014; Liu et al., 221 
2017). Knockdown of LRP1 was recently shown to block the uptake of monomeric and oligomeric 222 
tau in a human neuroglioma cell line, and partially inhibit uptake of sonicated tau fibrils (Rauch et 223 
al., 2020), warranting further investigation into how astrocytic LRP1 may mediate tau uptake and 224 
spread in tauopathies. 225 
Astrocytes are an integral part of the glymphatic system of the brain, a clearance system of soluble 226 
proteins and solutes. The astrocytic water channel aquaporin-4 (AQP4), expressed at the astrocyte 227 
end feet, facilitates this process and is important for Aβ clearance (Benarroch, 2007; Iliff et al., 228 
2012). Disruption to AQP4 may also contribute to tauopathy progression. In a mouse model of CTE, 229 
knockout of AQP4 exacerbated neurofibrillary tau pathology and neurodegeneration (Iliff et al., 230 
2014). Distinct phosphorylation marks in AQP4 have been reported in human post-mortem ARTAG 231 
samples relative to controls (Ferrer et al., 2018) that are suggested to increase water permeability of 232 
AQP4. However, the functional implications of these modifications in ARTAG remain to be 233 
explored (Han et al., 1998; Kitchen et al., 2015).  A recent transcriptional analysis of cognitively-234 
impaired subjects and controls showed that components of the dystrophin-associated complex, which 235 
anchors AQP4 at the perivascular astrocytic end foot, are associated with phosphorylated tau levels in 236 
the temporal cortex (Simon et al., 2018). This analysis also revealed other astrocyte endfoot 237 
candidate genes that significantly correlate with temporal cortex tau pathology. The authors speculate 238 
that endfoot functions of astrocytes may play a role in the accumulation of tau aggregates throughout 239 
the brain. Although AQP4 might contribute to the clearance of aberrant proteins early in the disease 240 
process, this function could become impaired at later stages, hindering the clearance of pathogenic 241 
tau. 242 
6 Tau effects on astrocyte function 243 
In addition to potential roles in tau spread, internalisation of pathological forms of tau has been 244 
shown to disrupt a myriad of astrocytic functions, central for the maintenance and support of 245 
neurons.  Oligomeric tau uptake alters calcium signalling and gliotransmitter release (e.g. ATP) via 246 
Ca2+-dependant mechanisms to disrupt post-synaptic currents and downregulate pre- and post-247 
synaptic markers in neuronal-astrocyte co-cultures (Piacentini et al., 2017), together suggesting that 248 
tau-induced changes to astrocyte function are toxic to neighbouring neurons, at least in vitro. 249 
Astrocytes isolated from a transgenic tauopathy model (P301S) expressing a 4R mutant tau isoform 250 
also acquired early functional deficiencies that impaired their ability to support neurons in culture 251 
(Sidoryk-Wegrzynowicz et al., 2017). Astrocytes from mouse models of tauopathies also show 252 
altered expression of neuronally regulated genes (Hasel et al., 2018), indicating that the accumulation 253 
of abnormal tau species is sufficient to drive transcriptional and likely functional changes in 254 
astrocytes, via altered neuron-astrocyte interactions. In addition, human astrocytes differentiated from 255 
iPSCs harbouring FTD-causing MAPT mutations display an increased vulnerability to oxidative 256 
stress and elevated protein ubiquitination, alongside disease-associated transcriptomic alterations 257 
(Hallmann et al., 2017).  258 
The immune-related functions of astrocytes are a major contributor to neuroinflammatory response 259 
that directly alter neuronal integrity in neurodegenerative diseases (Sofroniew and Vinters, 2010). In 260 
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particular, the complement cascade, which also involves microglia, has an important role in the 261 
accumulation of beta-amyloid pathology (Veerhuis et al., 2011; Lian et al., 2016). C3 is a major 262 
component of the complement cascade and is highly expressed in reactive astrocytes (Liddelow et al., 263 
2017). C3, as well as its downstream receptor C3aR1, that is mainly expressed by microglia, (Zhang 264 
et al., 2014), is upregulated in postmortem tauopathy brain and correlates with cognitive decline 265 
during disease progression (Litvinchuk et al., 2018). Levels of C3 also correlate with tau amounts in 266 
AD CSF (Wu et al., 2019). Ablation of C3aR or C3 in mouse models of tauopathy reversed neuronal 267 
loss and neurodegeneration (Litvinchuk et al., 2018; Wu et al., 2019), alongside reduced numbers of 268 
GFAP-reactive hypertrophied astrocytes being apparent upon C3aR knockout (Litvinchuk et al., 269 
2018). These data indicate that complement activation downstream of astrocyte reactivity may be an 270 
important driver of tauopathy.  271 
Astrocytes, together with microglia, are also hypothesized to induce synaptic loss and neurotoxicity 272 
in tauopathies, as they do during development (Chung et al., 2013), through dysregulated synaptic 273 
pruning (Henstridge et al., 2019). Sleep deprivation is common in AD (Noble and Spires-Jones, 274 
2019), where it is believed to be both a cause and consequence of neurodegenerative changes (Noble 275 
and Spires-Jones, 2019). Sleep deprivation leads to enhanced tau release and spread (Holth et al., 276 
2019), alongside astrocyte-mediated synapse elimination (Bellessi et al., 2017). It is therefore 277 
possible that astrocyte engulfment of tau-containing synapses may be one route by which astrocytes 278 
contribute to tau spread in AD.   279 
Ultimately, cross-talk between astrocytes and microglia forms part of a complex innate immune 280 
response that may be exacerbated during tauopathies in response to protein aggregates. Deeper 281 
investigation of these pathways may reveal novel targets that can be exploited to slow or halt disease 282 
progression.  283 
7 Discussion 284 
Recent evidence has highlighted that altered astrocyte functions have detrimental consequences for 285 
neurons and may be a driver of neurodegenerative diseases. Astrocytes are closely associated with 286 
the accumulation of pathological forms of tau in tauopathies. There is some evidence that astrocytes 287 
internalise tau aggregates, via mechanisms that are not yet fully understood, and contribute to tau 288 
pathology spread across the brain and tau aggregate clearance via the glymphatic system. However, 289 
astrocytes show significant regional heterogeneity and more work is needed to better understand the 290 
contribution of different astrocyte subtypes in affected brain regions at different disease stages. Such 291 
understanding may aid in the development of astrocyte-targeted therapies for tauopathies. Astrocyte-292 
targeted therapeutic approaches have been well described elsewhere including by Sadik and 293 
Liddelow (2019), and could include antagonists that prevent tau uptake by astrocytes to reduce tau 294 
spread, agents that prevent the release of neurotoxic astrocyte secretions or their uptake by neurons, 295 
or therapies that restore physiological astrocyte functions including their trophic support for neurons 296 
and synapses, maintenance of the blood brain barrier, and roles in the glymphatic clearance of protein 297 
aggregates.  298 
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 641 
11 Figure legends 642 
Figure 1. Astrocytic mechanisms that may contribute to spread of tau pathology. 1) Tau monomers 643 
and aggregates are released from neurons via various mechanisms, including from the pre-synapse, 2) 644 
Astrocytes have specific HSPGs and receptors such as LDR1 that may mediate the uptake of tau 645 
aggregates, 3) These aggregates may be internalised and processed by various mechanisms, include 646 
lysosomal degradation, 4) Disruption of AQP4 in perivascular astrocytic end-feet may contribute to 647 
the disrupted tau clearance and the accumulation of tau aggregates in the CNS. 648 
HSPG, heparin sulfate proteoglycan; LDR1, low density lipoprotein receptor-related protein 1; 649 
AQP4, aquaporin-4 650 
  651 
  
12 Tables 652 
Disease PiD PSP CBD AGD GGT ARTAG AD PART CTE 
Common 
clinical 
symptoms 
Aphasia, 
several 
behavioural 
changes 
including and 
personality 
changes, 
cognitive 
changes at 
later stages of 
disease. 
Balance and 
motor deficits, 
dysphagia and 
aphagia. 
Motor 
problems 
(often one-
sided), 
aphagia, 
dysphagia. 
Amnestic mild 
cognitive 
impairment 
often 
accompanied 
by 
neuropsychiatr
ic symptoms. 
Behavioural 
changes, mood 
swings, short-
term memory 
loss. 
Often no  
cognitive 
impairment 
or dementia 
related 
symptoms. 
Focal 
pathology 
may 
correlate 
with 
specific 
deficits, 
especially in 
the presence 
of co-
pathology.  
Dementia; 
progressive 
episodic 
memory 
deficits; 
navigational 
and multi-
tasking 
difficulties; 
diverse 
behavioural 
and 
personality 
changes. 
Associated 
with 
cognitive 
impairment 
and mild 
AD-like 
symptoms.  
Behavioural 
changes, mood 
swings, short-
term memory 
loss. 
MAPT 
cause/risk 
Mostly 
sporadic; 
MAPT 
mutations 
(exon 9, 10, 
11, 12, 13 and 
intron 9, 10). 
Mostly sporadic,  
H1/H1c MAPT 
haplotype 
increases risk; 
MAPT 
mutations (exon 
1, 10, and intron 
10); 
 
Mostly 
sporadic; 
H1 MAPT 
haplotype 
increases risk;  
MAPT 
mutations 
(exon 10, 13 & 
intron 10); 
 
H1 MAPT 
haplotype may 
increase risk; 
MAPT 
mutations 
(exon 10) 
H1 MAPT 
haplotype;  
MAPT 
mutations 
(exons 1, 10, 
11, intron 10). 
Depending  
on sub-type 
and 
classificatio
n 
Mostly 
sporadic; 
APP, 
PSEN1, 
PSEN2; 
No MAPT 
mutations 
Depending 
on sub-type 
and 
classificatio
n 
Unknown 
(external causes) 
Primary tau 
isoforms that 
3R 4R 4R 4R 4R 4R 3R & 4R 3R & 4R 3R & 4R 
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19 
accumulate in 
lesions 
Affected 
brain regions  
 
Frontal and 
temporal 
cortices. 
Precentral 
cortex, 
subcortex 
(globus pallidus, 
substantia nigra, 
pontine nuclei, 
subthalamic 
nuclei). 
 
Frontal and 
temporal 
cortices. 
Medial 
temporal lobe. 
Frontal, 
precentral 
and/or 
temporal 
cortices. 
Grey and/or 
white 
matter, 
perivascular
, subpial, 
subependym
al. 
Entorhinal 
cortex and 
hippocampu
s, spreading 
to most 
regions 
except the 
cerebellum. 
Entorhinal 
cortex, 
hippocampu
s. 
Begins focally at 
depths of 
cerebral sulci, 
spreads widely 
to frontal 
temporal lobes. 
Hallmark 
astrocytic tau 
pathology 
Ramified  
 
 
 
 
Tufted Astrocytic 
plaques 
Thorn-shaped 
& granular 
fuzzy/bush-
like 
Globular 
inclusions 
Thorn-
shaped & 
granular 
fuzzy 
None None Astrocytic 
tangles and 
some thorn-
shaped 
astrocytes. 
Cellular 
localisation of 
astrocytic tau 
inclusions 
Asymmetric 
3R 
(predominant) 
or 4R tau 
inclusions in 
cell bodies & 
proximal 
processes. 
Symmetric 4R 
tau inclusions in 
proximal 
processes. 
4R tau in 
distal 
processes and 
end feet; 
thread-like 
processes are 
also common. 
4R tau 
inclusions and 
diffuse 
staining in cell 
bodies & 
proximal-
distal 
processes. 
4R globular tau 
in cell bodies 
& proximal 
processes.  
4R tau 
inclusions 
and diffuse 
staining in 
cell bodies 
& proximal 
processes. 
n/a n/a Irregular p-tau 
lesions (around 
small vessels). 
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 653 
Table 1:  Overview of the main clinical, genetic, molecular, and pathological features of tauopathies, including description of astrocyte 654 
abnormalities.  655 
PiD, Pick’s disease; PSP, progressive supranuclear palsy; CBD, corticobasal degeneration; AGD, argyrophilic grain disease; GGT, globular 656 
glial tauopathy; ARTAG, age-related tau astrogliopathy; AD, Alzheimer’s disease; PART, primary age‑related tauopathy; CTE, chronic 657 
traumatic encephalopathy; 3R, 3-repeat tau; 4R, 4-repeat tau. 658 
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